# Junta clínica — PT-pseudo_25007bb807d7 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_25007bb807d7",
  "pid": "PT-pseudo_25007bb807d7",
  "task": 1,
  "psa": 17.0,
  "age": 61,
  "months": 1,
  "pirads": "5",
  "psad": 0.462,
  "psav": 1.29,
  "psap": 16.1,
  "vol": 36.82,
  "dre": "Normal",
  "bx": "None",
  "cspca": 0.85766834,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 17 ng/mL. PI-RADS 5. PSAD 0.46. Prostate volume 37 mL. csPCa 0.86.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "83 kg",
    "height": "193 cm",
    "bmi": "22.3",
    "bp": "122/68 mmHg",
    "hr": "74 bpm",
    "smoking": "Ex-smoker (16 pack-yr, quit 2015)",
    "last_dental": "3 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "19 Jan 2025",
  "enc_ref": "Dr. R. van den Berg (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Persistent prostate-specific antigen elevation prompted mpMRI scheduling."
    },
    {
      "s": "History",
      "t": "A 61-year-old office administrator entered the clinical pathway after a sustained prostate-specific antigen rise spanning three years. Lower urinary tract symptoms are minimal, scoring four on the IPSS questionnaire, while haematuria, pelvic discomfort, and unexplained weight loss are absent. Smoking history totals 16 pack-years, with cessation occurring in 2015; weekend hiking and roughly 11 units of alcohol weekly characterize his routine. He resides with his wife, who acts as his primary contact. Recent ophthalmological intervention involved uneventful cataract surgery, necessitating large-print materials for correspondence. Cardiovascular status remains stable, confirmed by a cardiology review in autumn 2024 that required no active interventions. There is a complete absence of prior urological procedures, comorbid conditions, or current medications."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth and symmetric; mobility: unrestricted; asymmetry: absent. General inspection shows a well-nourished individual with stable vital signs, alongside an absence of palpable lymphadenopathy or hepatosplenomegaly."
    }
  ],
  "occupation": "office administrator",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Cardiology — annual review (stable, autumn 2024)"
  ],
  "alcohol": "11 units / week",
  "exercise": "Hiking on weekends",
  "ipss": "IPSS score: 4/35 (mild LUTS)",
  "admin": "Visual impairment: large-print correspondence requested.",
  "mri_hospital": "Amsterdam UMC (location VUmc)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_25007bb807d7
Task: 1

Encounter: Urology - outpatient on 19 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 61-year-old male
  - PSA: 17.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.462 ng/mL²
  - PSA velocity: 1.29 ng/mL/yr
  - Prior PSA: 16.1 ng/mL
  - Prostate volume: 36.82 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.85766834 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 17 ng/mL. PI-RADS 5. PSAD 0.46. Prostate volume 37 mL. csPCa 0.86.

Vitals: weight 83 kg, height 193 cm, BMI 22.3, BP 122/68 mmHg, HR 74 bpm. Smoking: Ex-smoker (16 pack-yr, quit 2015).

Chief complaint: Persistent prostate-specific antigen elevation prompted mpMRI scheduling.

History: A 61-year-old office administrator entered the clinical pathway after a sustained prostate-specific antigen rise spanning three years. Lower urinary tract symptoms are minimal, scoring four on the IPSS questionnaire, while haematuria, pelvic discomfort, and unexplained weight loss are absent. Smoking history totals 16 pack-years, with cessation occurring in 2015; weekend hiking and roughly 11 units of alcohol weekly characterize his routine. He resides with his wife, who acts as his primary contact. Recent ophthalmological intervention involved uneventful cataract surgery, necessitating large-print materials for correspondence. Cardiovascular status remains stable, confirmed by a cardiology review in autumn 2024 that required no active interventions. There is a complete absence of prior urological procedures, comorbid conditions, or current medications.

Physical examination: DRE — texture: smooth and symmetric; mobility: unrestricted; asymmetry: absent. General inspection shows a well-nourished individual with stable vital signs, alongside an absence of palpable lymphadenopathy or hepatosplenomegaly.

Patient info: office administrator; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 11 units / week; exercise Hiking on weekends; IPSS score: 4/35 (mild LUTS).

Recent other appointments: Cardiology — annual review (stable, autumn 2024).
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: BIOPSY   p(biopsy) = 0.81
  uncertainty  +/- 0.07 (95% CI 0.66-0.95); among patients it cannot tell apart the outcome was 0.70 of 1.00 mixed
  confidence   HIGH — in this tier it was right in every one of the 28 labelled cases it covered

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like the classifier, I have read ONLY the visible panel — not the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory panel. Departing from me needs a specific
finding from a document somebody actually opened, named out loud. Not a restatement of the
panel numbers I already used.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline suggests that a PI-RADS threshold of $\ge 3$ is used to trigger biopsy. It also notes that adding perilesional sampling to targeted biopsy could mitigate the drawbacks of the MRI pathway by maintaining good detection of csPCa while decreasing the overdiagnosis of insignificant cancer.

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of biopsy is not sufficiently informed by the guideline because it fails to account for the specific threshold of PI-RADS 3 or higher that the guideline uses. Furthermore, the classifier's bid does not incorporate the guideline's nuance regarding the addition of perilesional sampling to targeted biopsy, which is a key element in the recommended strategy.

WHAT WE STILL NEED
The mpMRI prose - The mpMRI prose does not compare against an earlier study, so the guideline does not support re-sampling based on this.
PSA trend - The PSA velocity of 1.29 ng/mL/yr is a known variable, but the guideline does not specify a threshold for this velocity in relation to the biopsy decision.
Previous notes - The previous notes state "Prior biopsy: None," which is a fact the guideline makes decisive regarding the need for a repeat biopsy.
Laboratory results - The PSA density of 0.462 ng/mL² is a known variable, but the guideline sets a threshold of $< 0.20 \text{ ng/mL/cc}$ for omitting biopsy when MRI is negative and clinical suspicion is low.
Family history of prostate cancer anamnesis - The family history of prostate cancer anamnesis is not reported, which is a fact the guideline makes decisive regarding the need to assess clinical suspicion.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on whether we establish the specific criteria from the EAU guideline regarding PI-RADS thresholds and the role of the PSA velocity and prior biopsy status.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine if the mpMRI prose compares against an earlier study.
  psa_trend (get_psa_trend) -> Establish the significance of the PSA velocity of 1.29 ng/mL/yr.
  previous_notes (get_previous_notes) -> Confirm the management context, specifically regarding the 'Prior biopsy: None' status.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. Does the mpMRI prose compare against an earlier study, as this is noted as a point of uncertainty for the guideline?
  Q2. What is the threshold for PSA velocity in relation to the biopsy decision, as the guideline does not specify one?
  Q3. What is the family history of prostate cancer anamnesis, as this is noted as a decisive factor for clinical suspicion?

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose compares against an earlier study: The report does not explicitly state whether the mpMRI compares against an earlier study, only that it is an evaluation of elevated PSA.
psa_trend
The significance of the PSA velocity of 1.29 ng/mL/yr: The trend shows a significant rise from 3.1 ng/mL in May 2024 to 17.0 ng/mL in Jan 2025.
previous_notes
Confirm the management context, specifically regarding the 'Prior biopsy: None' status: Previous notes confirm "Prior biopsy: None" as of the consultation date.

WHAT I DID NOT OPEN
I did not open the laboratory_results because the moderator did not specifically ask for them in the plan, and the key variables needed for the decision were covered by the other requested documents.

WHAT THIS SUPPORTS
FOR sampling this patient now
mpMRI report: PI-RADS 5 lesion is a strong indicator.
previous_notes: Prior biopsy status is documented as "None".
AGAINST sampling this patient now
psa_trend: The PSA velocity of 1.29 ng/mL/yr is a known variable, but the guideline does not specify a threshold for this velocity in relation to the biopsy decision.

WHERE THIS LEANS
The findings strongly suggest a need for further investigation given the PI-RADS 5 score and the lack of prior biopsy.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar answered Q1 by stating the mpMRI prose does not explicitly state if it compares against an earlier study. The registrar answered Q2 by describing the PSA velocity trend, but did not state a threshold. The registrar answered Q3 by confirming the prior biopsy status, but did not provide the family history.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the classifier's suggestion of biopsy because the registrar noted the PI-RADS 5 lesion and the "Prior biopsy: None" status, which are variables the classifier weighted.

THE OPEN QUESTIONS, ONE BY ONE
Q1. Does the mpMRI prose compare against an earlier study, as this is noted as a point of uncertainty for the guideline? Not answered by the registrar; the report does not explicitly state this.
Q2. What is the threshold for PSA velocity in relation to the biopsy decision, as the guideline does not specify one? Not answered by the registrar; the registrar noted the velocity but did not state a threshold.
Q3. What is the family history of prostate cancer anamnesis, as this is noted as a decisive factor for clinical suspicion? Not answered by the registrar; this information was not retrieved.

WHAT CARRIES WEIGHT, AND WHY
The variables carrying weight are the PI-RADS 5 score because it is a strong indicator of concern, the prior biopsy status because it is documented as "None," and the PSA velocity because it is a known variable, although the guideline is silent on its threshold. The guideline does not support leaning on the PSA velocity threshold.

MY SUGGESTION TO THE CHAIR
Given the PI-RADS 5 score and the absence of a prior biopsy, the evidence leans towards proceeding with a biopsy, despite the lack of explicit guideline thresholds for the PSA velocity and family history.

VERDICT: ready | SUGGEST: biopsy | MISSING: family-history anamnesis

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Given the PI-RADS 5 score and the absence of a prior biopsy, the evidence strongly supports proceeding with a biopsy. The PI-RADS 5 finding is a strong indicator, and the lack of prior pathology means this is new information requiring investigation. The cohort and classifier both suggested biopsy, and the verifier confirmed readiness.

What carried weight: bx=noted, age=important, psa=important, vol=noted, psad=important, cspca=noted, pirads=decisive, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
